US – Bayer’s first-in-class nonsteroidal drug Kerendia is now available in the US for use following an approval as a therapy that can slow chronic kidney disease progression in patients with type 2 diabetes. The approval is based on data from the Phase III FIDELIO-DKD renal outcomes study, which showed Kerendia significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care. Kerendia also lowered the risk of a composite of time to first occurrence of cardiovascular…
Read MoreBayer’s Kerendia can now be used in USA as therapy for chronic kidney disease in type 2 diabetes patients
